Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Octreotide cycle length: what human studies ran

FDA-approvedAHuman trial evidence
Short answer: Octreotide has no "cycle". As an approved drug it is used as its label and a prescriber direct.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Octreotide combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Octreotide cycle length?
No cycle is defined. Octreotide is an approved drug whose label describes treatment under a prescriber's care; the label, not a cycle, governs duration.
What is the longest human study of Octreotide?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Octreotide dosing reference Full research page

References

  1. SANDOSTATIN (octreotide acetate) injection, prescribing information (DailyMed SPL version 23, published Jul 24, 2026) FDA label (DailyMed). 2026
  2. SANDOSTATIN LAR DEPOT (octreotide acetate) for injectable suspension, prescribing information (DailyMed SPL version 29, published Dec 23, 2025) FDA label (DailyMed). 2025
  3. MYCAPSSA (octreotide) delayed-release capsules, prescribing information (DailyMed SPL version 6, published Jul 28, 2025) FDA label (DailyMed). 2025
  4. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol. 2009
  5. Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide J Clin Endocrinol Metab. 2020
  6. Tractatenblad 2026 Nr. 25: Anti-doping convention (ETS No. 135), amendment to the appendix - The 2026 Prohibited List, World Anti-Doping Code (English text; entry into force 1 January 2026) Tractatenblad van het Koninkrijk der Nederlanden (official government publication). 2026
  7. PubChem compound record for octreotide (CID 448601) PubChem. 2026